Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria.

Weiss JP, van der Meulen EA, Juul KV.

Eur Urol Focus. 2018 Nov 20. pii: S2405-4569(18)30333-X. doi: 10.1016/j.euf.2018.11.001. [Epub ahead of print]

PMID:
30470646
2.

A Danish population-based cohort study of desmopressin use in adults with nocturia or nocturnal enuresis.

Juul KV, Schrøder MK, Mahler B, Rittig S, Nørgaard JP.

Low Urin Tract Symptoms. 2018 Jul 11. doi: 10.1111/luts.12229. [Epub ahead of print]

PMID:
29992760
3.

Desmopressin use in pediatric nocturnal enuresis patients: is there a sex difference in prescription patterns?

Schroeder MK, Juul KV, Mahler B, Nørgaard JP, Rittig S.

Eur J Pediatr. 2018 Mar;177(3):389-394. doi: 10.1007/s00431-017-3074-x. Epub 2017 Dec 19.

PMID:
29260376
4.

Recent advances in managing and understanding enuresis.

Van Herzeele C, Walle JV, Dhondt K, Juul KV.

F1000Res. 2017 Oct 24;6:1881. doi: 10.12688/f1000research.11303.1. eCollection 2017. Review.

5.

An exploratory pilot study with copeptin as a biomarker for individualizing treatment for nocturnal polyuria.

Bruneel E, Goessaert AS, Denys MA, Juul KV, Nørgaard JP, Everaert K.

Low Urin Tract Symptoms. 2017 Oct 23. doi: 10.1111/luts.12192. [Epub ahead of print]

PMID:
29057582
6.

Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.

Rovner ES, Raymond K, Andruczyk E, Juul KV.

Low Urin Tract Symptoms. 2018 Sep;10(3):221-230. doi: 10.1111/luts.12169. Epub 2017 May 31.

PMID:
28560762
7.

Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia.

Juul KV, Malmberg A, van der Meulen E, Walle JV, Nørgaard JP.

BJU Int. 2017 May;119(5):776-784. doi: 10.1111/bju.13718. Epub 2016 Dec 10.

8.

The analgesic action of desmopressin in renal colic.

Kapila V, Kapila AK, Tailly T, Rappe B, Juul KV, Everaert K.

Acta Clin Belg. 2017 Jun;72(3):179-185. doi: 10.1080/17843286.2016.1230569. Epub 2016 Sep 23. Review.

PMID:
27658643
9.

Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels.

Juul KV, Jessen N, Bliwise DL, van der Meulen E, Nørgaard JP.

Endocrine. 2016 Sep;53(3):722-9. doi: 10.1007/s12020-016-0920-y. Epub 2016 Mar 22.

PMID:
27003433
10.

Delay Of Optimal Nocturia Treatment Is Costly: Results Of A Real World Survey Of Patients In Europe And The Usa.

Andersson FL, Anderson P, Juul KV, Wood R, Piercy J, Weiss JP.

Value Health. 2015 Nov;18(7):A511. doi: 10.1016/j.jval.2015.09.1475. Epub 2015 Oct 20. No abstract available.

11.

Hrqol And Utility In Nocturia Are Correlated To Number Of Voids.

Andersson FL, Juul KV, Raymond K, Rosen RC.

Value Health. 2015 Nov;18(7):A511-2. doi: 10.1016/j.jval.2015.09.1477. Epub 2015 Oct 20. No abstract available.

12.

Desmopressin as an adjuvant to opioids or NSAIDs in treatment of renal colic: a nationwide register-based study.

Juul KV, Schroeder MK, Rittig S, Nørgaard JP.

Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1155-60. doi: 10.1002/pds.3875. Epub 2015 Sep 9.

PMID:
26349846
13.

Delay of first voiding episode is associated with longer reported sleep duration.

Bliwise DL, Holm-Larsen T, Goble S, Juul KV, van der Meulen E, Nørgaard JP.

Sleep Health. 2015 Sep;1(3):211-213. doi: 10.1016/j.sleh.2015.05.001. Epub 2015 Jul 20.

PMID:
29073442
14.

Re: A systematic review of the efficacy and safety of desmopressin for nocturia in adults: M. H. Ebell, T. Radke and J. Gardner J Urol 2014;192:829-835.

Nørgaard JP, Juul KV, Gupta J.

J Urol. 2015 May;193(5):1729; discussion 1730. doi: 10.1016/j.juro.2014.11.101. Epub 2015 Feb 3. No abstract available.

PMID:
25660473
15.

Nocturia is associated with loss of deep sleep independently from sleep apnea.

Bliwise DL, Dijk DJ, Juul KV.

Neurourol Urodyn. 2015 Apr;34(4):392. doi: 10.1002/nau.22724. Epub 2015 Jan 16. No abstract available.

PMID:
25640210
16.

Management of nocturia: the role of antidiuretic pharmacotherapy.

Weiss JP, Juul KV, Wein AJ.

Neurourol Urodyn. 2014 Apr;33 Suppl 1:S19-24. doi: 10.1002/nau.22592. Review.

PMID:
24729149
17.

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E.

Blood Rev. 2014 May;28(3):95-102. doi: 10.1016/j.blre.2014.03.001. Epub 2014 Mar 22. Review.

PMID:
24703870
18.

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

Juul KV, Bichet DG, Nielsen S, Nørgaard JP.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F931-40. doi: 10.1152/ajprenal.00604.2013. Epub 2014 Mar 5. Review.

19.

National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients.

Juul KV, Schroeder M, Rittig S, Nørgaard JP.

J Clin Endocrinol Metab. 2014 Jun;99(6):2181-7. doi: 10.1210/jc.2013-4411. Epub 2014 Feb 14.

PMID:
24527719
20.

Clinical review: Treatment of neurohypophyseal diabetes insipidus.

Oiso Y, Robertson GL, Nørgaard JP, Juul KV.

J Clin Endocrinol Metab. 2013 Oct;98(10):3958-67. doi: 10.1210/jc.2013-2326. Epub 2013 Jul 24.

PMID:
23884783

Supplemental Content

Loading ...
Support Center